Dr. Yin commented, "Sinovac Beijing has been a leader in the human vaccineindustry with its inactivated hepatitis A vaccine, Healive(TM), and hascommanded the leading market position in China. We are pleased to receivethis award that recognizes our high growth of 290% over the past three years.We continue to advance our vaccine technology and leverage our marketadvantages to increase sales of our commercialized vaccines. We are wellpositioned to continue our growth in light of the world financial crisis andincreasing competition."

As one part of the Deloitte Technology Fast 500 Asia Pacific program, theDeloitte Technology Fast 50 China ranking includes the 50 fastest growingtechnology, media, telecommunications and life sciences companies in China andthe Asia Pacific region. The Fast 50 China 2008, as determined by Deloitte &Touche, LLP, a US-based professional services organization, aims to reward andraise the visibility of the companies with highest growth rates. Among the2008 China recipients, six companies come from biotechnology andpharmaceutical industry, representing 12%, a 4% increase compared to the lastyear. The increase demonstrates the rapid development and expansion of thelife sciences industry in China.

In conjunction with the awards ceremony, Deloitte released the "CEO SurveyReport on Deloitte's Technology Fast 50 China 2008." The report noted thatthe rapid development of technology leads to research advances, new technology,and new products. Approximately 60% of interviewed CEOs believe the organicgrowth based on new technologies and products has greatly promoted businessexpansion.

Similar to last year, Chinese growth companies continue to have a highregard for growth prospects across the Asia Pacific region. 71% of thesurveyed companies have an optimistic view of development in the region.These CEOs also believe the Asia Pacific region presents the most attractivemarket growth opportunities. Additionally, 77% of CEOs said they pay muchmore attention to the regional market, which is attracting enterprises seekingadvanced development opportunities.

Talking about future, 94% of CEOs remain confident that the region willcontinue to experience a high growth rate over the next 12 months. 46% ofCEOs do not believe the world economic depression has affected their business.They are actively adopting corresponding measures, such as attracting talentfrom developed markets and seeking acquisition opportunities in the developedmarkets.

About the Deloitte Technology Fast 50

The Deloitte Technology Fast 50 program started in 1995 in San Jose. Thisprogram quickly expanded to numerous cities and countries. In 2005, DeloitteChina launched the "Deloitte Technology Fast 50 China" program. Participantsin the Deloitte Technology Fast 50 China program will automatically qualifyfor participation in the Deloitte Technology Fast 500 Asia Pacific 2008program, which annually recognises the 500 fastest growing technologycompanies in Asia Pacific.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company thatfocuses on the research, development, manufacture and commercialization ofvaccines that protect against human infectious diseases. Sinovac'scommercialized vaccines include Healive(R) (hepatitis A), Bilive(R) (combinedhepatitis A and B), Anflu(R) (influenza) and Panflu(TM) (H5N1). Sinovac iscurrently developing Universal Pandemic Influenza vaccine and Japaneseencephalitis vaccine. Additional information about Sinovac is available onits website, http://www.sinovac.com . To be added to our distribution list,please email: info@sinovac.com.

Safe Harbor Statement

This announcement contains forward-looking statements. These statementsare made under the "safe harbor" provisions of the U.S. Private SecuritiesLitigation Reform Act of 1995. These forward-looking statements can beidentified by words or phrases such as "will," "expects," "anticipates,""future," "intends," "plans," "believes," "estimates" and similar statements.Among other things, the business outlook and quotations from management inthis press release contain forward-looking statements. Statements that arenot historical facts, including statements about Sinovac's beliefs andexpectations, are forward-looking statements. Forward-looking statementsinvolve inherent risks and uncertainties. A number of important factors couldcause actual results to differ materially from those contained in anyforward-looking statement. Sinovac does not undertake any obligation toupdate any forward-looking statement, except as required under applicable law.

For more information, please contact: Helen G. Yang Sinovac Biotech Ltd. Tel: +86-10-8289-0088 x9871 Fax: +86-10-6296-6910 Email: info@sinovac.com Investors/Media: Stephanie Carrington / Janine McCargo The Ruth Group Tel: +1-646-536-7017/7033 Email: scarrington@theruthgroup.com / jmccargo@theruthgroup.comSOURCE Sinovac Biotech Ltd.